Abdul Rafae

I put together a free guide on using AI the right way in medicine. How to use it as a teacher. Where the ethical line is. 45+ research databases. Formal AI courses from AMA, AAMC, Harvard, Stanford. For medical students, IMGs, residents, and fellows: linkedin.com/posts/faiz-anw…

@YusraMedik @UAMS @uamshealth @uamscancer @KArnaoutakis Congratulations Yusra! Such a great achievement! Keep up the good work.

I wrote about my experience at the Vail Workshop for ASCO Connection: “Five Stages of the Vail Workshop: A Fellow’s Perspective.” Grateful for the mentorship and support at @UAMS @uamshealth @uamscancer @KArnaoutakis

JUST IN: The report we always look for every year: CANCER STATISTICS, 2026 New milestone with 5y Survival of 70%!!! Still a lot of room to improve but also excellent progress ! @AmericanCancer @CACancerJournal @DanaFarber acsjournals.onlinelibrary.wiley.com/doi/10.3322/ca…

Treatment of Multiple Myeloma: ASCO–Ontario Health (Cancer Care Ontario) Living Guideline | Journal of Clinical Oncology @JCO_ASCO @ASCO #mmsm ➡️ ascopubs.org/doi/10.1200/JC…

When programs reward numbers, trainees chase numbers. When programs reward thinking, trainees become physicians.

This slide perfectly illustrates the paradox of modern HR+ metastatic breast cancer management. On paper, the post–CDK4/6 landscape is elegant and biologically rational: NGS-guided decisions, ESR1-targeted oral SERDs, PI3K/AKT pathway inhibitors, PARP inhibitors, and even CDK4/6 continuation strategies. Almost every resistance mechanism has a proposed solution. In real life, however—in many countries, including my own—most of these red-highlighted options are simply not accessible. The algorithm exists, the evidence exists, the biomarkers exist… but the treatments do not. So the question is unavoidable: who is this progress really for? If we cannot deliver these drugs to patients, daily discussions about ever-expanding therapeutic menus risk becoming purely theoretical exercises. Theoretical knowledge alone is not enough; translating it into practice is essential, but this is unfortunately not in the hands of physicians. It is a global problem. So, where were we? What were we supposed to give patients with ESR1 mutations, those with PIK3CA alterations, and those with co-mutations? And then the questions keep coming: what if the DFI is less than 12 months? If ctDNA turns positive before radiologic progression—was that SERENA-6 or PADA-1? After every conference, I find myself trapped in this paradox. Hopefully, one day everyone will have fair access to the treatments they deserve. Wishing you a nice weekend—it was a good conference. #SABCS25

Management of Cancer During Pregnancy: ASCO Guideline It is a remarkably comprehensive guide that addresses every question thoroughly👇 ascopubs.org/doi/10.1200/JC…

In 2025, many important and long-awaited studies were published. I included them but kept the algorithms unchanged, as there are open questions about how these data will impact practice, particularly in early and metastatic HER2+ disease and mTNBC. @DFCI_BreastOnc #SABCS25

@hhashmi87 @Dr_AmerZeidan @VincentRK How do you define Dara exposed vs Dara Refractory? Is there a certain timeperiod post dara you would think patient will respond to Dara+Tec in 2L as they did in the original trial?

Great Qs and we are all passionately discussing these. See @VincentRK posts with #MSmart guidelines. 1) IMO, If pt is Dara naive/exposed but not Dara Refractory, Dara+Tec is as effective as CAR T in 2L. 2) Yes, Tec (MajesTEC-7) & Cilta-cel (CAR T-6) are both being studied in 1L for TI & TIE #MMSM. Phase I/II BsAb in frontline is showing exceptional responses (MajestTEC-5, TecLille, LINKER-MM4) 3) I would consider CR (preferably MRD neg) at 1y to stop Rx

I am not a myeloma doctor & don’t follow field closely but for those who are I have 3 questions-1) how do you use these results with wide frontline use of dara in USA and 2) is tec or other bites being studied in frontline randomized Ph3? 3) how long would you give this for?

Highlights from #ASH25 #CommunityOnc: #Lymphoma 1. #EPCOREFL1 FL 2. #CLL17 CLL 3. #BRUIN313/314 CLL 4. #S1826 HL #Myeloma 5. #COBRA 6. #MajesTEC3 7. #AQUILA 8. #RedirecTT1 #Leukemia 9. #PARADIGM @ASH_hematology #lymsm #mmsm #HemeTwitter 1/10

It’s time for #ASH25! Here is a📝 of 🔑studies from #CommunityOncologists perspective. - #BRUINCLL313 - #WINDOW3 - #ALPINE - #MajesTEC3 - #MRD in Myeloma - #COBRA - #AUGMENT101 - #GimemaALL2820 - #VAYHIT2 - #VERIFY #mmsm #lymsm #leuksm #HemeTwitter @ASH_hematology

@allisonoconn I’m gonna put out there that we truly have no ideas how ADCs work…pmc.ncbi.nlm.nih.gov/articles/PMC11…

BCMA-Based Therapies in Multiple Myeloma #mmsm Summary of the approved drugs/combinations targeting BCMA with details on approval date, lines of therapy, supportive studies, common AEs as well as need for REMS Updated 10/2025

Wow. All the benefit of checkpoint inhibition in A-BRAVE (high-risk TNBC) was seen in patients with TILs ≥ 30%. No benefit with low TILs. Unbelievable that we didn’t get to see the TILs data from KN522 yet. Hope we’ll see them soon. Congrats @vitti10! #ESMO25 #ESMOAmbassadors

The bar is raised! Periop 🥪 EVP for cis ineligible (90%) or refusing (10%) MIBC = new SOC *KN905/EV302* ✅pT0 rate highest ever in MIBC 57% ITT, 65% cystectomy sub-pop ✅2yr EFS & OS on par w DDMVAC in cis eligible -cis eligible EVP🥪 trial *KNB15/EV304* readout awaited #ESMO25

Important data from monarchE and NATALEE adjuvant CDK46 inhibitor @myESMO With @tess_omeara, here's our take on who needs, and who does not need, adjuvant abema/ribo, co-published in @Annals_Oncology annalsofoncology.org/article/S0923-…

🚨 #ESMO25 | ASCENT-03 (LBA20) 🧬 Sacituzumab Govitecan (SG) vs physician’s-choice chemo in 1L PD-L1-negative or IO-ineligible mTNBC Results (n = 558; median FU 13.2 mo): Median PFS: 9.7 mo vs 6.9 mo → HR 0.62 (0.50-0.78), p < 0.0001 ✅ ORR: 48.4 % vs 45.5 % Median DOR: 12.2 mo vs 7.2 mo OS: immature Safety: G3+ AEs ≈ 66 % vs 62 % Neutropenia 43 % / 41 %, diarrhea 9 %, anemia 16 % Tx discontinuation 4 % vs 12 % → better tolerability 📈 Interpretation: SG delivers a clinically meaningful PFS gain (~3 mo) and more durable responses, with manageable toxicity. 💡 Context: Comparable PFS to KEYNOTE-355 (IO + chemo ≈ 9.7 mo), showing ADC monotherapy can rival IO + chemo in PD-L1–negative or IO-ineligible mTNBC. Looking forward to discussion on esmo day 3 #ESMO25 @myESMO @OncoAlert

One week to #ESMO25. An unprecedented ESMO conference. Seven positive press releases, anticipating the expansion of T-DXd to the curative setting, two Trop2 ADCs reaching first-line mTNBC, 2 novel ET-based combos, adjuvant CDK4/6i improving OS. See you in Berlin! #ESMOAmbassadors

~2 wks to #ESMO25! Here’s a📝of🔑studies for GeneralOnc that could change/reinforce SoC: - #DESTINYBreast 05&11 - #monarchE & #NATALEE - #VIKTORIA1 - #FORTITUDE01 - #DYNAMIC3 - #STELLAR303 - #KN905 - #IMVigor011 - #PSMAddition - #MDTBridge #OncTwitter @myESMO @OncoAlert

📣Durva-FLOT was added to NCCN guidelines of gastric and GEJ adenoca ✅For PDL1 positive tumors, category 1 ✅CPS or TAP ✅PDL1 testing is recommended universal, not just for advanced disease #cancer #oncology #MedX #gastric @OncoAlert @ASCO @myESMO @brunolarvol @SuyogCancer